Company Overview

Karyopharm Therapeutics Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. The company operates primarily in the oncology sector and is best known for developing selective inhibitors of nuclear export (SINE) compounds that target exportin 1 (XPO1), a protein involved in transporting tumor suppressor proteins out of the cell nucleus. Karyopharm’s lead commercial product is XPOVIO (selinexor), which has received regulatory approvals in multiple hematologic cancer indications, including multiple myeloma and diffuse large B-cell lymphoma. The company generates revenue primarily from product sales, licensing arrangements, and collaboration agreements related to its oncology pipeline.

Karyopharm was founded in 2008 and is headquartered in Newton, Massachusetts. The company emerged from research focused on nuclear transport biology and advanced its proprietary SINE platform into clinical-stage development. Over time, it evolved from a research-focused biotechnology company into a commercial oncology enterprise following U.S. Food and Drug Administration approvals for selinexor. Karyopharm’s strategic positioning centers on its proprietary expertise in nuclear export inhibition and its ability to develop orally administered oncology therapies targeting difficult-to-treat cancers.

Business Operations

Karyopharm’s operations are centered on oncology drug development and commercialization through its primary business segment, oncology therapeutics. The company’s principal revenue driver is sales of XPOVIO in the United States, supported by collaborations and licensing partnerships in international markets. Karyopharm has also developed additional clinical-stage compounds, including eltanexor, a second-generation oral XPO1 inhibitor under investigation for hematologic malignancies and solid tumors. The company maintains intellectual property related to its SINE technology platform and leverages this portfolio to support pipeline development and strategic collaborations.

The company conducts operations primarily in the United States while utilizing partnerships for broader international reach. Karyopharm has entered into licensing and commercialization agreements with external pharmaceutical companies for select territories outside the U.S., including arrangements in parts of Asia and Europe. Its operational model combines internal research and clinical development capabilities with outsourced manufacturing and collaborative commercialization structures. The company’s activities are heavily influenced by regulatory approvals, clinical trial progression, and oncology market adoption trends.

Strategic Position & Investments

Karyopharm’s strategic direction has focused on expanding the clinical utility of selinexor and advancing next-generation XPO1 inhibitors through clinical development programs. Growth initiatives have included evaluating selinexor in combination therapies, pursuing label expansions in hematologic malignancies, and investigating potential applications in solid tumors. The company has also concentrated on extending the commercial reach of XPOVIO through physician education, payer engagement, and international licensing agreements.

In recent years, Karyopharm has prioritized capital allocation toward pipeline optimization and late-stage clinical programs. The company has maintained collaborations with academic institutions and oncology research networks to support clinical development. Its strategic investments are primarily directed toward proprietary oncology assets rather than diversified acquisitions. Public filings and investor disclosures indicate that Karyopharm continues to evaluate opportunities involving targeted oncology therapeutics and translational cancer research while managing operating expenses and cash runway considerations typical of commercial-stage biotechnology companies.

Geographic Footprint

Karyopharm is headquartered in Newton, Massachusetts, and its principal commercial operations are concentrated in the United States. The company markets XPOVIO domestically and supports clinical development activities through partnerships with hospitals, cancer centers, and contract research organizations. Its U.S. presence represents the core of its revenue-generating operations and regulatory activities.

Internationally, Karyopharm has established market access through licensing and commercialization agreements in regions including Europe and Asia-Pacific. The company’s global footprint is driven primarily by strategic partnerships rather than direct large-scale infrastructure investments abroad. Clinical trials have involved multinational participation across several continents, supporting broader regulatory engagement and international oncology development efforts.

Leadership & Governance

Karyopharm Therapeutics operates under a leadership structure focused on oncology commercialization, clinical development, and capital discipline. The company’s governance framework includes executive leadership with backgrounds in biotechnology, pharmaceuticals, finance, and drug development. Public company disclosures, including SEC filings, identify strategic priorities centered on maximizing the value of its oncology portfolio and advancing pipeline assets through data-driven clinical execution.

Key members of leadership have included:

• Richard Paulson – President and Chief Executive Officer
• Michael G. Kauffman, MD, PhD – Founder and former Chief Executive Officer
• Sharon Shacham, PhD, MBA – Founder, President and Chief Scientific Officer
• Owen A. O’Connor, MD, PhD – Chief Medical Officer
• Christopher Brett – Chief Operating Officer
• David Happel – Executive Vice President and Chief Financial Officer

The company’s leadership philosophy has emphasized scientific innovation in nuclear export biology, disciplined oncology drug development, and targeted commercialization in hematologic malignancies. Governance practices are overseen by a board of directors consistent with U.S. public biotechnology company standards and regulatory disclosure requirements.